Role of miR-21 in chronic lung disease

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K10186
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Embryonic/Neonatal medicine
• Research Institution: Fukushima Medical University
• Principal Investigator: Hayato Go 福島県立医科大学, 医学部, 講師 (30443857)
• Co-Investigator(Kenkyū-buntansha): 桃井 伸緒 福島県立医科大学, 医学部, 教授 (10285033) ; 橋本 浩一 福島県立医科大学, 医学部, 准教授 (50322342)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 新生児慢性肺疾患 / Extracellular vesicles / Exosome / microRNA / miR-21

Outline of Final Research Achievements

Serum EVs were extracted from premature infants at birth and on the 28th day of life (DOL). Using a human miRNA array, we identified 62 miRNAs that were universally expressed in CLD patients and non-CLD patients. Of these miRNAs, serum EV miR-21 was upregulated in CLD patients on DOL28 compared with levels at birth and downregulated in non-CLD patients on DOL28 compared with levels at birth. . We conclude that EV miR-21 may be a biomarker of CLD. In CLD mouse model exposed to hyperoxia, pulmonary function in mice after injection of miR-21 inhibitor was improved. This suggests that miR-21 could be a potential therapeutic target for CLD.

Free Research Field

新生児慢性肺疾患

Academic Significance and Societal Importance of the Research Achievements

本研究では、miR-21が新生児慢性肺疾患のバイオマーカーになり得ることを示し、さらに動物実験ではmiR-21を制御することでCLDマウスの呼吸機能が改善していたため、miR-21が新生児慢性肺疾患の治療標的となり得る可能性が示唆された。